UNSPSC 51183203: Isaglidole

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) B51UC955KQ. European Medicines Agency schedules Isaglidole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08301MIG. Isaglidole generally arises in the molecular formula C11H13FN4.

UNSPSC 51183203 Isaglidole (Commodity) covers pharmaceutical active ingredients and finished-dosage products that state and local governments procure through cooperative purchasing vehicles and direct supply agreements. The recent activity under this code centers on generic multi-source pharmaceuticals and over-the-counter products distributed to state and local healthcare facilities, correctional systems, and related public institutions. State governments and cooperative purchasing alliances are the primary buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses this code to aggregate demand across multiple states for volume pricing and simplified procurement. Vendors supplying under this code must hold current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certifications, maintain relationships with FDA-authorized wholesalers (such as AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, or Morris & Dickson), and submit detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. Insurance requirements include commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Products must have expiration dates of at least one year from manufacture and a minimum six-month shelf life.

The code shows recent activity in Minnesota and participating states including Oregon through MMCAP's multi-state model. The Minnesota Department of Administration's Office of State Procurement issued an RFP (S1070000015802) on January 20, 2026, for Generic Multi-Source Pharmaceuticals and OTC Products with a response deadline of March 26, 2026. Award decisions will be weighted primarily on price competitiveness (75 percent), with secondary weight on fixed pricing structure (10 percent), EDI capability and administrative fee compliance (5 percent each), and administrative data format compliance (5 percent). Contract terms run two years for new vendors and extend through June 30, 2028, for incumbents. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Vendors should anticipate a 3 percent administrative fee on all contract purchases and potential performance penalties of $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.